Table 1.

Studies with Analysis of cfDNA/ctDNA in OC or EC Patients

References	Country	Cancer Type	Sources	Cancer/Control	Abnormalities	Methodology	Clinical Relevance
Shao et al34	China	OC	Serum	36/41	Level	bDNA technique	Diagnosis
Kamat et al35	USA	OC	Plasma	164/124	Level	RT-PCR	Diagnosis
Kamat et al36	USA	OC	Plasma	19/12	Level	RT-PCR	Diagnosis
Zachariah et al37	Switzerland	OC	Serum/plasma	21/83	Level	RT-PCR	Diagnosis
Dobrzycka et al38	Poland	OC	Plasma	126/NA	Level/KRAS mutation	PCR-RFLP	Diagnosis/prognosis
Cicchillitti et al39	Italy	EC	seRum	59/NA	Level	RT-PCR	Diagnosis
Dobrzycka et al40	Poland	EC	Plasma	109/NA	Level	PCR-RFLP	Diagnosis
Vizza et al41	Italy	EC	Serum	60/NA	Level	RT-PCR	Diagnosis
Tanaka et al42	Japan	EC	Plasma	53/24	Level	RT-PCR	Diagnosis/prognosis
Hickey et al43	United Kingdom	OC	Serum	20/NA	Mutations, LOH and MI	PCR	Diagnosis
Otsuka et al46	Japan	OC	Plasma	27/NA	p53 mutation	PCR	Diagnosis/prognosis
Park et al47	Korea	OC	Plasma	4/NA	TP53 mutation	Digital PCR	Diagnosis
Cohen et al49	Australia	OC	Plasma	32/32	Chromosomal instability	Whole genome NIPT platform	Diagnosis
Vanderstichele et al50	Belgium	OC	Plasma	57/11	Chromosomal instability	NGS	Diagnosis
Phallen et al51	USA	OC	Plasma	42/NA	Somatic mutations	TEC-Seq	Diagnosis
Farkkila et al52	Finland	OC	Plasma	35/NA	FOXL2 mutation	ddPCR	Diagnosis/prognosis
Sun et al53	China	EC	PBLs	139/139	mtDNA copy number value	RT-PCR	Diagnosis
Giannopoulou et al56	Greece	OC	Plasma	59/NA	RASSF1A methylation	MSP technique	Diagnosis
Zhang et al57	China	OC	Serum	87/115	(APC, RASSF1A, CDH1, RUNX3, TFPI2, SFRP5, OPCML) methylation	MSP technique	Diagnosis
Liggett et al58	USA	OC	Plasma	30/60	(RASSF1A, CALCA, EP300, BRCA1, CDKN1C, PGR-PROX) methylation	MethDet 56	Diagnosis
Melnikov et al59	USA	OC	Plasma	33/33	(BRCA1, HIC1, PAX5, PGR, THBS1) methylation	MethDet 56	Diagnosis
Widschwendter et al60	UK	OC	Serum	25/598	(COL23A1, C2CD4D, WNT6) methylation	NGS	Diagnosis/prognosis
Li et al61	China	OC	Peripheral blood	206/205	Methylation at multiple sites	NGS	Diagnosis
Wu et al62	China	OC	Plasma	47/24	RASSF2A methylation	MSP technique	Diagnosis
Ibanez et al63	USA	OC	Serum/plasma	50/NA	(BRCA1, RASSF1A) methylation	MSP technique	Diagnosis
Margolin et al67	USA	EC	A computational simulation	42/8	ZNF154 methylation	NGS	Diagnosis
Wimberger et al71	Germany	OC	plasma	62/28	Level	RT-PCR	prognosis
Perkins et al72	United Kingdom	OC	Plasma	105/20	Level/mutations in 19 genes	NGS	Prognosis
Steffensen et al73	Denmark	OC	Plasma	144/NA	Level	RT-PCR	Prognosis
No et al74	Korea	OC	Plasma	36/16	(B2M, RAB25, CLDN4, ABCF2) mutation	RT-PCR	Prognosis
Kuhlmann et al75	Germany	OC	Serum	63/20	Level/LOH	Fluorescence-labeled PCR	Prognosis
Swisher et al48	USA	OC	Plasma/serum	137/NA	p53 mutation	DNA sequencing	Prognosis
Giannopoulou et al76	Greece	OC	Plasma	129/NA	ESR1 methylation	MSP technique	Prognosis
Bolivar et al70	USA	EC	Plasma	48/NA	(CTNNB1, KRAS, PTEN, PIK3CA) mutation	NGS	Prognosis
Harris et al77	USA	OC	Plasma	8/NA	Chromosomal junctions	Quantitative PCR	Prognosis
Pereira et al78	USA	OC and EC	Serum	22OC,17EC/NA	Level	Digital PCR	Prognosis
Du et al79	China	OC	Plasma	21/NA	Mutations/CNV	NGS	Prognosis
Martignetti et al80	USA	OC	Plasma/serum	1/NA	FGFR fusions	NGS/RT-PCR	Prognosis
Choudhuri et al82	India	OC	Plasma	100/NA	Level	RT-PCR	Treatment response
Capizzi et al83	Italy	OC	Plasma	22/NA	Level	RT-PCR	Treatment response
Arend et al84	USA	OC	plasma	14/NA	level	NGS	Treatment response
Kamat et al69	USA	OC in mice	Plasma	–	Level	RT-PCR	Treatment response
Parkinson et al68	United Kingdom	OC	Plasma	40/NA	TP53 mutation	Digital PCR	Treatment response
Gifford et al85	United Kingdom	OC	Plasma	138/NA	hMLH1 methylation	Microsatellite PCR	Treatment response
Flanagan et al86	United Kingdom	OC	Peripheral blood	247/NA	Methylation at CpG sites	NGS	Treatment response
Matulonis et al90	USA	OC	Plasma	67/NA	Mutations in components/modulators of the PI3K pathway	NGS/Sanger sequencing	Treatment response
Weigelt et al87	USA	OC	Plasma	19/NA	BRCA reversion mutation	NGS	Treatment response
Christie et al88	Australia	OC	Plasma	30/NA	BRCA reversion mutation	NGS	Treatment response
Lin et al89	USA	OC	Plasma	209/NA	BRCA reversion mutation	NGS	Treatment response

Abbreviations: OC, ovarian cancer; EC, endometrial cancer; bDNA, branched DNA; PCR-RFLP, PCR-restriction fragment length polymorphism; LOH, loss of heterozygosity; MI, microsatellite instability; NGS, next-generation sequencing; mtDNA, mitochondrial DNA; ddPCR, digital droplet PCR; PBLs, peripheral blood leukocytes; MSP, methylation-specific PCR; CNV, copy number variation; NK, do not know.